CPS1 and sarcopenia: While AAV8.Null with AAV8.cre recombinase mice developed progressive weight loss and sarcopenia beginning at 14 days after administration of vectors (Figures 2C and 2D, red squares), AAV8.CPS1 mice demonstrated stability of weight throughout the studies (blue triangles).